TY  - JOUR
AU  - Wu, Zhaoquan 
AU  - Sun, Wei 
AU  - Wang, Chunjiang
TI  - Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease
PY  - %2026/%06/%22
Y2  - %2026/%08/%27
JF  - Sarcoidosis, Vasculitis and Diffuse Lung Diseases
JA  - Sarcoidosis Vasc Diffuse Lung Dis
VL  - 43
IS  - 2
SE  - Original Articles: Clinical Research
DO  - 10.36141/svdld.2026.18699
UR  - https://doi.org/10.36141/svdld.2026.18699
SP  - 18699
AB  - Background To investigate the clinical features of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) -associated interstitial lung disease (ILD), and to provide a reference for the rational use of ALK TKI.Methods Cases of ALK TKI-associated ILD before December 31, 2025 were collected by searching the database and clinical data were collected for retrospective analysis.Result Fifty patients were included, with a median age of 54.5 years (range 33, 86). The median time of ILD occurrence was 50 days (range 2, 630). Dyspnea (56.0%), hypoxemia (38.0%), cough (36.0%) and fever (26.0%) were the main clinical symptoms, and there may also be no symptoms. Computed tomography mainly showed ground-glass opacities (98.0%). After the patients discontinued ALK-TKI and received systemic steroid treatment, 90.0% of the patients had symptom relief and improved imaging, and 10.0% of the patients died.Conclusion ILD is a rare and fatal adverse event of ALK-TKI. The possibility of ILD should be considered if dyspnea, hypoxemia, and cough occur during ALK-TKI use. After ILD recovery, patients could switch to the same ALK-TKI or another ALK-TKI under the protection of glucocorticoid.
ER  -